- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00653120
Bioavailability Study of Propranolol Under Fasting Conditions
April 1, 2008 updated by: Par Pharmaceutical, Inc.
Comparative, Randomized, Single-Dose, 2 Way Cross Over Bioavailability Study of Par Propranolol 160 mg With That of Inderal-LA Propranolol 160 mg in Healthy Subjects Under Fasting Conditions.
To compare the single-dose bioavailability of Propranolol 160 Mg ER capsules with Inderal-La
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
To compare the single -dose bioavailability of Par Propranolol 160 Mg ER capsules with Wyeth Pharmaceuticals, Inderal-LA, Propranolol under fasting conditions.
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Quebec
-
Sainte- Foy, Quebec, Canada, G1V2K8
- SFBC Anapharm
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects enrolled in the study will be members of the community at large. The Recruitment advertisements may use various media types (E.g. ratio, newspapers, SFBC Anapharm Website, SFBC Anapharm volunteer's database). Subjects must meet all the following criteria in order to be included in the study.
- Male and female, non-smoker, 18 years of age and older
- Capable of consent
- BMI ≥ 19.0 and > 30.0 kg/ m2.
Exclusion Criteria:
- Subjects to whom any of the following applies will be excluded from the study.
- Clinically significant illness within 4 weeks prior to the administration of the study medication
- Clinically significant surgery within 4 weeks prior to the administration of the study medication.
- Any clinically significant abnormality found during medical screening.
- Any reason which, in the opinion of the Medical Sub- Investigator, would prevent the subject from participating in the study.
- Abnormal laboratory tests judged clinically significant.
- Positive testing for hepatitis B, hepatitis C, or HIV at screening.
- ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood pressure lower than 100 or over 140 mmHg, diastolic blood pressure lower than 60 or over 90 mmHg, or heart rate less than 60 or over 100 bpm) at screening.
- History of significant alcohol abuse or drug abuse within one year prior to the screening visit.
- Regular use of alcohol within six months prior to the screening visit (more than fourteen units of alcohol per week [ 1 Unit = 150mL of wine, 360 mL of beer, or 45mL of 40% alcohol])
- Use of soft drugs ( such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine [PCP] and crack) within 1 year prior to the screening visit or positive urine drug at screening.
- History of allergic reactions to heparin, propranolol, or other related drugs.
- Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of inducers: barbiturates, carbamazepine, phenytoin,glucocorticoids , omerprazole; examples of inhibitors: antidepressants (SSRI), cimetidine, diltiazem, macrolides, imidazoles, neuroleptics, verapamil, fluoroquinolones, antihistamines) within 30 days prior to administration of the study medication.
- Use of an investigational drug or participation in an investigational study within 30 days prior to administration of the study medication.
- Clinically significant history or presence of any clinically significant gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases), unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney disease, or other conditions known as interface with the absorption, distribution, metabolism, or excretion of the drug.
- Any clinically significant history or presence of clinically significant neurological, endocrinal, cardiovascular, pulmonary, hematologic, psychiatric, or metabolic disease.
- Use of prescription medication within 14 days prior to administration of a study medication or over the counter products (including natural food supplements, vitamins, garlic as a supplement) within 7 days prior to administration of study medication, except for topical products without systemic absorption and hormonal contraceptive.
- Difficulty to swallow study medication.
- Use of any tobacco products in the 6 months proceeding drug administration.
- Any food allergy, intolerance, restriction or special diet that, in the opinion of the Medical Sub- Investigator, could contraindicate the subject's participation in this study.
- A depot injection or an implant of any drug (other than contraceptives) within 3 months prior to administration of study medication.
- Donation of plasma (500 Ml) within 7 days to drug administration. Donation or loss of whole blood (excluding the volume of blood drawn during the screening procedures of this study) prior to administration of the study medication as follows.
- 50mL to 300mL of whole blood within 30 days, 301 mL to 500 ml of whole blood within 45days or more than 500 mL of whole blood within 56 days prior to drug administration..
- History bronchial asthma and bronchospastic diseases.
- History of known presence of cardiogenic shock, sinus bradycardia, Wolff-Parkinson White Syndrome, congestive heart failure or angina.
- Clinically significant history of diabetes.
- Clinically significant history of hyperthyroidism.
- Breast- feeding subject.
- Positive urine pregnancy test at screening.
- Female subjects of childbearing potential having unprotected sexual intercourse with any non- sterile male partner (i.e. male who ahs not been sterilized by vasectomy for al least 6 months) within 14 days prior to study drug administration. Acceptable methods of contraception:
- Intra-uterine contraceptive device (place al least 4 weeks prior to study drug administration)
- Condom or diaphragm. + spermicide
- Hormonal contraceptives (starting al least 4 weeks prior to study administration)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: A
Subjects received Par Products under fasting conditions
|
ER capsules, 160 mg, single-dose
Other Names:
|
Active Comparator: B
Subjects received Wyeth Pharmaceuticals product under fasting conditions
|
ER capsules, 160 mg, single-dose
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate and Extend of Absorption
Time Frame: 24 Hours
|
24 Hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Denis Audet, SFBC Anapharm
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2005
Primary Completion (Actual)
November 1, 2005
Study Completion (Actual)
November 1, 2005
Study Registration Dates
First Submitted
April 1, 2008
First Submitted That Met QC Criteria
April 1, 2008
First Posted (Estimate)
April 4, 2008
Study Record Updates
Last Update Posted (Estimate)
April 4, 2008
Last Update Submitted That Met QC Criteria
April 1, 2008
Last Verified
April 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 40451
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on To Determine Bioequivalence Under Fasting Conditions
-
Par Pharmaceutical, Inc.Novum Pharmaceutical Research ServicesCompletedTo Determine the Bioequivalence Study Under Fasting
-
Par Pharmaceutical, Inc.Algorithme Pharma IncCompletedTo Determine the Bioequivalence Study Under FastingCanada
-
Par Pharmaceutical, Inc.BASi Clinical Research UnitCompletedTo Determine Bioequivalence Under Fasting ConditionsUnited States
-
Par Pharmaceutical, Inc.AAI ClinicCompletedTo Determine Bioequivalence Under Fasting Conditions
-
Par Pharmaceutical, Inc.AnapharmCompletedTo Determine Bioequivalence Under Fasting ConditionsCanada
-
Par Pharmaceutical, Inc.AnapharmCompletedTo Determine Bioequivalence Under Fasting ConditionsCanada
-
Par Pharmaceutical, Inc.AnapharmCompletedTo Determine Bioequivalence Under Fasting ConditionsCanada
-
Par Pharmaceutical, Inc.AnapharmCompletedTo Determine Bioequivalence Under Fasting ConditionsCanada
-
Par Pharmaceutical, Inc.Phoenix International Life Sciences, Inc.CompletedTo Determine Bioequivalence Under Fasting ConditionsCanada
-
Par Pharmaceutical, Inc.Cetero Research, San AntonioCompletedTo Determine the Bioequivalence Under Fasting ConditionsUnited States
Clinical Trials on Propranolol
-
University of UtahTerminated
-
University Hospital, GenevaSuspendedStage IB Skin Melanoma | Stages III Skin Melanoma | Stages II Skin MelanomaSwitzerland
-
Mela, Mansfield, M.D.UnknownPosttraumatic Stress Disorder | Traumatic MemoryCanada
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Completed
-
Douglas Mental Health University InstituteInstitut de Recherche Robert-Sauvé en Santé et en Sécurité du TravailRecruitingTrauma and Stressor Related Disorders | Post-traumatic Stress Disorders | Adjustment Disorders | Acute Stress DisorderCanada
-
Govind Ballabh Pant HospitalUnknownHepatic EncephalopathyIndia
-
Taipei Veterans General Hospital, TaiwanUnknownCirrhosis | Acute Kidney Injury | Esophageal VaricesTaiwan
-
Kent State UniversityAkron Children's Hospital; Ohio Board of RegentsCompletedPosttraumatic Stress Disorders
-
Vanderbilt UniversityCompleted
-
Assiut UniversityUnknown